November 6, 2012 ·
Leave a comment
November 6, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in Canada focused on key opinion leaders and medical centers of excellence in women’s health with an international biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products aimed at improving the health of women, approached Thought Leader Select for support in a variety of collaborative efforts with leading physicians and other health care professionals at leading universities, medical schools, teaching hospitals, and specialty clinics. The key opinion leaders represent medical experts within the Canadian obstetrics and gynecology community, with areas of sub-specialty including fertility and the treatment of uterine tumors.
Known for the versatility of applications for its in-house research and analysis, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians and other health care professionals, including registered nurses, physician assistants, nurse practitioners, clinical pharmacists, and medical researchers, to advance the science of medicine and patient care in women’s health, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening collaborative ... read more »
TAGS: 
biopharmaceutical company biotechnology Canadian KOLs centers of excellence Chapel Hill NC clinical research clinical trials deep-profiling drug development gynecology health care professionals health care providers healthcare key opinion leaders KOL KOL deployment KOL engagement KOL identification KOL mapping KOL profiling KOLs Kristen Smithwick medical experts medical research obstetrics scientific journal publishing Thought Leader Select thought leaders transparency treatment guidelines uterine tumors women's health
October 18, 2012 ·
Leave a comment
October 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement focused on medical centers of excellence in obesity with a top U. S. biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating the condition of obesity, approached Thought Leader Select for support with a variety of collaborative efforts, including medical science liaison outreach to leading universities, medical schools, teaching hospitals, and specialty clinics in this area. Having already worked with Thought Leader Select to form rosters of key opinion leaders in endocrinology, primary care, nursing, pharmacy, and long-term care in the treatment of type I and type II diabetes and obesity, the company has now chosen Thought Leader Select to pinpoint the leading centers of excellence in the treatment of obesity in the United States.
Known for the versatility of applications for its in-house research and analysis, Thought Leader Select’s research group will assess the skills and experience of selected centers, detailing the collaborative activities of leading physicians and other health care professionals, including registered nurses, physician assistants, nurse practitioners, clinical pharmacists, and medical researchers, the people who advance the science of medicine and patient care, through basic and clinical research, scientific journal ... read more »
TAGS: basic research biopharmaceutical industry biotechnology Brian Castle centers of excellence identification centers of excellence profiling centers of excellence strategy clinical pharmacists clinical research drug development endocrinology health care professionals key opinion leaders KOL identification KOL profiling KOL strategy long-term care medical device industry medical diagnostics medical researchers medical schools medical science medical science liaison outreach nursing obesity obesity centers of excellence obesity KOLs patient care pharmaceuticals pharmacy physician assistants physicians primary care medicine registered nurses scientific journal publishing specialty medical clinics teaching hospitals Thought Leader Select Thought Leader Select consulting group Thought Leader Select research group treatment guidelines type 1 diatbetes type 2 diabetes universities
October 4, 2012 ·
Leave a comment
(CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a national engagement in obesity with a top U. S. biopharmaceutical company.
The company, part of a select group of global leaders in drug development for products treating the condition of obesity, approached Thought Leader Select for support with scientific advisory boards, consulting, and medical science liaison outreach to leading physicians in this area. Having already worked with Thought Leader Select to form rosters of key opinion leaders in endocrinology, primary care, nursing, pharmacy, and long-term care in the treatment of type I and type II diabetes, the company has now chosen Thought Leader Select to pinpoint the leading experts in the treatment of obesity in the United States.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of specialists in multiple areas where they collaborate with leading physicians to advance the science of medicine and patient care, including basic and clinical research, scientific journal publishing, treatment guidelines, and more.
Throughout the remainder of the engagement, Thought Leader Select’s consulting team will provide strategic guidance, tactical recommendations for strengthening key opinion leader relationships in the area of obesity, and a suite of tools to promote collaborative work ... read more »
TAGS: advisory boards biopharmaceutical biotechnology Brian Castle clinical research drug development health care professionals health care providers healthcare key opinion leader key opinion leaders KOL KOL engagement KOL identification KOL mapping KOL profiling KOLs medical experts medicine obesity obesity key opinion leaders obesity specialists public health
June 14, 2012 ·
Leave a comment
June 14, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a global engagement in blood disorders with a top 30 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for a product in development to treat iron overload in the body, approached Thought Leader Select for support with its launch activities across multiple global markets. To meet the strategic needs of the company’s pre-launch for a new blood disorders treatment, Thought Leader Select will deploy its in-house research group for an assessment of key opinion leaders in the area of chelation therapy.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following geographic areas:
- United States
- Europe
- Japan
- Pacific Rim
- Middle East
For the global assessment, the Thought Leader Select research group will identify 100 physicians appropriate for compliant engagement in support of drug development for blood disorders.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought ... read more »
TAGS: advisory boards basic research biopharmaceutical biotechnology blood disorders chelation therapy clinical research clinical trials drug development drug launch iron overload key opinion leader relationships key opinion leaders KOL KOL engagement KOL identification KOL profiling KOL reserch Kristen Smithwick medical congresses medical experts Neil Mellor pharmaceutical physicians scientific journal publishing Thought Leader Select treatment guidelines
April 26, 2012 ·
Leave a comment
April 26, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of an inter-disciplinary infectious disease engagement with a top 10 global biopharmaceutical company.
The biopharmaceutical company, part of a select group of global leaders in drug development for the treatment of infectious diseases, approached Thought Leader Select for support with its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s emerging pipeline in treating conditions like HIV and Hepatitis-C, Thought Leader Select will deploy its in-house research group for a multi-disciplinary assessment of the key opinion leader community in infectious diseases.
Known for the versatility of applications for its in-house research, Thought Leader Select’s research group will analyze the skills and experience of leading specialists in the following areas:
Gastroenterology
Hepatology
Infectious Disease
Internal Medicine
For the first wave of the assessment, the Thought Leader Select research group will identify 50 physicians appropriate for compliant engagement in support of drug development for infectious diseases, across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as thought leaders, ... read more »
TAGS: basic and clinical research biopharmaecutical consulting firm diagnostics drug development gastroenterology geographic impact of key opinion leaders health care professionals Hepatitis C hepatology HIV infectious diseases internal medicine key opinion leader relationships key opinion leaders KOL KOL engagement KOL identification KOL mapping KOL profiling KOL strategy Kristen Smithwick market access medical affairs medical device medical marketing medical meetings speakers patient health payer marketing physicians pipeline planning pricing and reimbursement professional network mapping public health scientific journal publishing Thought Leader Select thought leaders in medicine treatment guidelines
April 18, 2012 ·
Leave a comment
April 18, 2012 (CHAPEL HILL, NC) Thought Leader Select, a Chapel Hill, NC-based consulting firm serving the biopharmaceutical, medical device, and diagnostics industries, announces the commencement of a urology engagement with a top 20 global pharmaceutical company.
The pharmaceutical company, a global leader in drug development for urological conditions, approached Thought Leader Select for support with its existing portfolio of medicines, as well as new drugs in its development pipeline across the Canadian market. To meet the combined strategic needs of the company’s existing portfolio as well as its emerging pipeline, Thought Leader Select will deploy its in-house research group for a two-part assessment of the key opinion leader community in urology.
For the first wave of the assessment, the Thought Leader Select research group will validate the skills and experience of the urology specialists that currently comprise the company’s KOL roster. In addition, Thought Leader Select will identify new physicians appropriate for the panel, bringing the total roster to 40 thought leaders across multiple Canadian provinces.
In the second phase of the assessment, Thought Leader Select’s in-house research group will engage in its exclusive, validated methodology of deep profiling, delivering objective assessments of the skills and experience of key opinion leaders across 14 areas where health care professionals define themselves as ... read more »
TAGS: basic and clinical research biopharmaceutical diagnostics drug development key opinion leaders KOL engagement KOL identification KOL panel KOL profiling KOL roster KOLs in urology Kristen Smithwick medical devices medical meetings pharmaceuticals scientific journal publishing Thought Leader Select thought leaders treatment guidelines urology
December 2, 2011 ·
Leave a comment
Thought Leader Select is pleased to announce a series of key opinion leader (KOL) identification and profiling projects to support multiple therapeutic areas for a top five global biopharmaceutical company.
In these research assessments, Thought Leader Select will identify and profile leading medical experts in neurology and oncology to support drug development initiatives in various cancers and neurological disorders. The oncologists and neurologists will represent many of the leading physicians at top medical centers of excellence throughout Canada.
Thought Leader Select will use its validated, objective deep profiling methodology to assess the skills and experience of the thought leaders in oncology and neurology in multiple research categories, including their areas of expertise, medical/scientific journal publishing history, and participation in basic and clinical research. The company’s research group is comprised of subject-matter experts in medicine, with decades of experience working in medical research and clinical settings in the United States, Canada, Australia, and Africa.
The project will yield over 100 physicians who may advise the company on its development efforts in the treatment of cancers and neurological diseases. Typically, key opinion leaders serve on scientific advisory boards and participate in late-stage clinical trials to monitor the effectiveness of new drugs in larger patient populations.
“We are honored that this company has chosen to partner with us again to use effective solutions to identify ... read more »
TAGS: basic research biopharmaceutical cancer treatment cancers clinical research clinical trials deep-profiling doctors drug development key opinion leaders KOL identification KOL profiling late-stage clinical trials medical experts medical journals medical research medicine neurological disorders neurology oncologists Oncology patient populations pharmaceuticals physicians prescription drugs scientific journals therapeutic areas Thought Leader Select thought leaders
July 19, 2011 ·
Leave a comment
Often, prospective clients ask us, “What do other clients do with your KOL research?” or “Will you please send examples of your research and its uses?”
We relish opportunities to share the applications for Thought Leader Select’s objective, validated expert identification, subject matter expert-driven deep profiling, and engagement services informed by industry leaders with decades of experience. Recently, the team developed a formal case study to showcase how one client, a top 20 pharmaceutical company, relies on Thought Leader Select to fuel and support its KOL relationship strategies and efforts in the treatment of diabetes.
Relationships with thought leaders in medicine help biopharmaceutical companies continue understanding and addressing the illnesses and diseases impacting all of us. To advance medicine and improve public health, medical professionals and biopharmaceutical companies must partner together, and they should base those partnerships on high levels of therapeutic expertise, an understanding of patient needs, and superior research insights and capabilities. Thought Leader Select is proud to support these important relationships with objective information that connects the right medical professionals with biopharmaceutical teams, for the right reasons, and at the right times.
Read our first case study, regarding our breadth of services in support of a biopharmaceutical company’s scientific development in the treatment of diabetes here: http://www.thoughtleaderselect.com/kol-services/kol-case-studies/.
TAGS: biopharmaceutical biotechnology case study deep-profiling drug development healthcare industry partnerships key opinion leaders KOL engagement KOL identification KOL mapping KOL profiling KOL relationship KOL research medicine objective research patient needs pharmaceutical public health therapeutic expertise Thought Leader Select thought leaders unmet medical needs validated research
July 8, 2010 ·
Leave a comment
In a recent study commissioned by a global pharmaceutical and medical device company, Thought Leader Select delivered an objective research assessment of the top 35 medical centers of excellence for the treatment of attention deficit disorder (ADD) and attention deficit hyperactivity disorder (ADHD) across the United States and Canada. For the assessment, Thought Leader Select analyzed information in several key areas, including basic and clinical research, publications, residency programs, and treatment guidelines involvement.
Within the scope of the overall assessment, the client company commissioned a more focused look at the top centers of excellence for research in the ADD/ADHD field. The top center’s profile included 11 ongoing clinical trials to evaluate the potential for new medicines to effectively treat ADD and ADHD. Previously, the center completed nine major studies evaluating the effectiveness of various treatment methods for the conditions, and the center had generated 18 clinical trial publications over a seven-year period.
In addition to the center’s array of landmark studies and clinical trial participation, the Thought Leader Select assessment also noted the center’s dominance in the area of publishing. For this category, the company used keywords relevant to the client’s focus within the therapeutic area to determine medical journal article relevancy. The center had generated a total of 94 publications in the treatment area of ADD/ADHD since 2001, with 67 of ... read more »
TAGS: ADD ADHD attention deficit disorder attention deficit hyperactivity disorder basic and clinical research biotechnology Canada centers of excellence clinical trials drug development medical centers medical devices medical journals pharmaceutical publications residency programs therapeutic area Thought Leader Select treatment guidelines United States
June 30, 2010 ·
Leave a comment
Industry Insights from Paul Meade, M. Sc, MPH
When a biopharmaceutical company introduces a new medicine to the market, it comes after years of research, years of clinical development, and some times even years of regulatory review. With the patent ticking away from the early days of discovery, recovering the cost of such an investment in time and money requires a rapid and successful product launch. Achieving rapid success requires careful planning and a tremendous amount of valuable advice. This sage advice usually comes from respected thought leaders with years of experience in their respective therapeutic areas of expertise.
>From the early discovery phase, key opinion leaders help guide a company’s basic research to ensure unmet medical needs are met in a meaningful and cost-effective way. After moving beyond the proof-of-concept stage and into clinical development, other thought leaders play a critical role in assisting with the design of clinical trials that will be implemented through a network of investigators. Throughout the clinical development phases, thought leaders help guide a company with the most important messages other physicians will hear about the strengths and weaknesses of such a new medicine. And finally, as this new product enters the marketplace and is prescribed by the medical community, thought leaders play an important role ... read more »
TAGS: basic research biomarker discovery biopharmaceutical biotechnology clinical development clinical investigators clinical trials doctors drug development drug discovery drug launch health care professionals key opinion leaders KOL activities KOL engagement KOL identification KOL profiling KOLs media medical experts medicine patents pathway development patient advocacy groups pharmaceutical physicians product launch regulatory review thought leaders
Older posts »
